MD Anderson-led global Phase III study finds that a PARP inhibitor plus immunotherapy lowers the risk of endometrial cancer progression over chemotherapy alone – MD Anderson Cancer Center

Quoting MD Anderson Cancer Center on LinkedIn:

“MD Anderson-led global Phase III study finds that a PARP inhibitor plus immunotherapy lowers the risk of endometrial cancer progression over chemotherapy alone.

“These findings showcase, for the first time, the potential of combining immunotherapy with a PARP inhibitor to deliver significant clinical improvements for these patients,” says lead investigator Shannon Westin.”